HIFU for Focal Ablation of Prostate Tissue: An Observational Study
Start Date
9/26/2018
Completion Date
1/31/2028
Summary
The Sonablate HIFU device was approved by the U.S.FDA for prostate tissue ablation in October, 2015. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using HIFU through clinical data and health-related quality of life (HRQOL) questionnaires.
Detailed Description
This observational study will serve to collect data from medical record review and questionnaires before and after High Intensity Focused Ultrasound (HIFU) for focal ablation of prostate tissue. The subject will have already undergone or opted to receive the HIFU procedure as part of standard of care in order to participate in this study.
Eligibility Criteria
Age Range: 40 years to 85 years
Interventions
Sonablate HIFU device
Conditions
Locations
University of California, Los Angeles
Los Angeles, California 90095
United States